A phase 2/3 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, now recruiting.
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients is a phase 2/3 interventional study registered as NCT07290088 by Intra-IMMUSG Pte Ltd, with 52 participants planned, started 2023-01-09 and due to reach its primary completion in 2026-12. Interventions recorded: PRL3-ZUMAB.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.